Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::NTRK3 status confers therapeutic sensitivity to Entrectinib in patients with Any solid tumor.
This statement is based on a regulatory approval from the Health Canada:
ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.